ArticleInternational journal of molecular sciences2025
A Pre-Clinical Study on the Use of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor PEP 2-8 to Mitigate Ischemic Injury in a Rat Marginal Donor Model.
Maria Antonietta Grignano et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.